Liberal RBC Transfusion Strategy for Brain Aneurysm

Phase-Based Progress Estimates
Brain AneurysmLiberal RBC Transfusion Strategy - Other
All Sexes
What conditions do you have?

Study Summary

This trial will help determine the best way to treat anemia in patients with aSAH, and whether doing so impacts mortality and functional outcomes.

Eligible Conditions
  • Brain Aneurysm

Treatment Effectiveness

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: 12 months post

12 months post
EuroQOL Quality of Life Scale (EQ5D)
Functional Independence Measure (FIM)
Length of Stay
Modified Rankin Scale (mRS)
up to 21 days
Daily Hemoglobin
Mechanical Ventilation
Red Blood Cell Transfusions
up to 28 days
Cerebral Infarction
Delayed Cerebral Ischemia and Vasospasm
Transfusion-related Complications

Trial Safety

Trial Design

2 Treatment Groups

Restrictive RBC Transfusion Strategy
1 of 2
Liberal RBC Transfusion Strategy
1 of 2

Active Control

Experimental Treatment

740 Total Participants · 2 Treatment Groups

Primary Treatment: Liberal RBC Transfusion Strategy · No Placebo Group · N/A

Liberal RBC Transfusion Strategy
Experimental Group · 1 Intervention: Liberal RBC Transfusion Strategy · Intervention Types: Other
Restrictive RBC Transfusion Strategy
ActiveComparator Group · 1 Intervention: Restrictive RBC Transfusion Strategy · Intervention Types: Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months post

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
529 Previous Clinical Trials
2,511,236 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,232 Previous Clinical Trials
24,674,912 Total Patients Enrolled
Shane English, MD MSc FRCPCPrincipal InvestigatorOttawa Hospital Research Institute
1 Previous Clinical Trials
60 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Diagnosis of aSAH as confirmed by treating physician (eg: neurosurgeon or neuro- interventionalist) and supported by blood in subarachnoid space (e.g.
Hb ≤100g/L within 10 days following aSAH (defined by first day of hospital presentation).